Review Article
Functionally Improved Mesenchymal Stem Cells to Better Treat Myocardial Infarction
Table 1
Clinical trials of MSC transplantation for treating MI.
| | Clinical trials | Phase | Dose (106) | Delivery route | Enrollment | Infarct scar | LVEF | Following up | Study | Reference |
| | NCT00114452 | Phase 1 | 0.5/1.6/5 | IC | 53 | n.a. | ↑ | 6 m | Hare et al. (2009) | [25] | | NCT00677222 | Phase 1 | 100 | IC | 30 | n.a. | ↑ | 4 m | Penn et al. (2012) | [26] | | 2011AA020109 | Phase 1 | 3.08 | IC | 43 | = | ↑ | 12 m | Gao et al. (2013) | [27] | | UO1 HL087318–04 | Phase 1 | 150 | IC | 65 | ↓ | ↑ | 12 m | Traverse et al. (2014) | [28] | | NCT01234181 | Phase 1 | 100 | IC | 22 | ↓ | ↑ | 12 m | Hu et al. (2015) | [29] | | NCT01087996 | Phase 1/2 | 20 | IM | 30 | ↓ | ↑ | 13 m | Hare et al. (2012) | [30] | | U54HL081028 | Phase 1/2 | 20 | IM | 30 | ↓ | ↑ | 13 m | Suncion et al. (2014) | [31] | | NCT02323477 | Phase 1/2 | 20 | IM | 79 | n.a. | n.a. | 12 m | Can et al. (2015) | [32] | | NCT00883727 | Phase 1/2 | 180–220 | IV | 20 | = | = | 2 y | Chullikana et al. (2015) | [33] | | NCT02504437 | Phase 1/2 | — | — | 200 | — | — | 12 m | Pei (2015–2017) | ClinicalTrials.gov | | NCT02503280 | Phase 1/2 | 200 | — | 55 | — | — | 12 m | Joshua (2015–2032) | ClinicalTrials.gov | | NCT02666391 | Phase 1/2 | — | — | 64 | — | — | 18 m | Pei (2016–2017) | ClinicalTrials.gov | | NCT01770613 | Phase 2 | — | — | — | — | — | 12 m | Nabil (2013–2017) | ClinicalTrials.gov | | NCT00684021 | Phase 2 | 150 | IC | 101 | n.a. | ↑ | 6 m | Schutt et al. (2015) | [34] | | NCT00984178 | Phase 2 | 15 | IC | 120 | ↓ | ↑ | 12 m | San Roman et al. (2015) | [35] | | NCT00765453 | Phase 2 | 59.8 | IC | 100 | n.a. | ↑ | 12 m | Choudry et al. (2015) | [36] | | NCT01291329 | Phase 2 | 6 | IC | 116 | ↓ | ↑ | 18 m | Gao et al. (2015) | [37] | | NCT03047772 | Phase 2 | — | — | 124 | — | — | 12 m | Yang (2017–2018) | ClinicalTrials.gov | | NCT00877903 | Phase 2 | — | IV | 220 | — | — | 5 y | Donna (2009–2018) | ClinicalTrials.gov | | NCT02013674 | Phase 2 | 100 | IM | 30 | ↓ | ↑ | 12 m | Florea et al. (2013–2019) | [38] | | NCT01392105 | Phase 2/3 | 72 | IC | 80 | n.a. | ↑ | 6 m | Lee et al. (2014) | [39] | | NCT03404063 | Phase 2/3 | 30 | | 115 | — | — | 6 m | Piotr (2017–2020) | ClinicalTrials.gov | | NCT01394432 | Phase 3 | — | IM | 50 | — | — | 12 m | Evgeny (2012–2016) | ClinicalTrials.gov | | NCT01652209 | Phase 3 | — | — | 135 | — | — | 13 m | Yang (2013–2020) | ClinicalTrials.gov | | NCT02672267 | Phase 3 | — | IM | 50 | — | — | 6 m | Saule (2014–2016) | ClinicalTrials.gov |
|
|
MSCs: mesenchymal stem cells; MI: myocardial infarction; IM: intramyocardial; IC: intracoronary; IV: intravenous; LVEF: left ventricular ejection fraction; y: year; m: month; n.a.: not analyzed; =: no statistical significance. , , and . |